Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017110094) CASPASE INHIBITOR-CONTAINING DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-β, AND APPLICATION THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/110094 International Application No.: PCT/JP2016/005216
Publication Date: 29.06.2017 International Filing Date: 22.12.2016
Chapter 2 Demand Filed: 24.05.2017
IPC:
A61K 45/00 (2006.01) ,A61K 31/197 (2006.01) ,A61K 31/4725 (2006.01) ,A61K 38/00 (2006.01) ,A61P 27/02 (2006.01) ,A61P 43/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
472
Non-condensed isoquinolines, e.g. papaverine
4725
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants:
学校法人同志社 THE DOSHISHA [JP/JP]; 京都府京都市上京区今出川通烏丸東入玄武町601番地 601 Gembu-cho, Karasuma-Higashi-iru, Imadegawa-dori, Kamigyo-ku, Kyoto-shi, Kyoto 6028580, JP
Inventors:
小泉 範子 KOIZUMI, Noriko; JP
奥村 直毅 OKUMURA, Naoki; JP
Agent:
山本 秀策 YAMAMOTO, Shusaku; JP
森下 夏樹 MORISHITA, Natsuki; JP
▲駒▼谷 剛志 KOMATANI, Takeshi; JP
飯田 貴敏 IIDA, Takatoshi; JP
石川 大輔 ISHIKAWA, Daisuke; JP
山本 健策 YAMAMOTO, Kensaku; JP
Priority Data:
2015-25178724.12.2015JP
Title (EN) CASPASE INHIBITOR-CONTAINING DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-β, AND APPLICATION THEREOF
(FR) MÉDICAMENT CONTENANT UN INHIBITEUR DE CASPASE POUR LE TRAITEMENT OU LA PRÉVENTION DE TROUBLE PROVOQUÉ PAR TGF-β, ET SON APPLICATION
(JA) カスパーゼ阻害剤を含む、TGF-βに起因する障害を治療または予防するための医薬およびその応用
Abstract:
(EN) Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth facto r-β (TGF-β) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.
(FR) L'invention concerne un médicament ou une méthode de traitement ou de prévention d'un état, d'un trouble ou d'une maladie de l'endothélium cornéen provoqué par des signaux du facteur de croissance transformant β (TGF-β) et/ou par des anomalies mitochondriales dans des cellules endothéliales cornéennes. La présente invention concerne un médicament comprenant des inhibiteurs de caspase, et qui est destiné au traitement ou à la prévention d'un état, d'un trouble ou d'une maladie de l'endothélium cornéen provoqué par des signaux TGF-β et/ou par des anomalies mitochondriales dans des cellules endothéliales cornéennes. Dans le mode de réalisation préféré, l'état, le trouble ou la maladie de l'endothélium cornéen est une dystrophie cornéenne endothéliale de Fuchs.
(JA) 角膜内皮細胞におけるトランスフォーミング増殖因子-β(TGF-β)シグナルおよびミトコンドリア異常の少なくとも1つに起因する角膜内皮の症状、障害または疾患の治療または予防するための医薬または方法を提供する。本発明は、カスパーゼ阻害剤を含む、角膜内皮細胞におけるTGF-βシグナルおよびミトコンドリア異常の少なくとも1つに起因する角膜内皮の症状、障害または疾患の治療または予防のための医薬を提供する。好ましい実施形態では、角膜内皮の症状、障害または疾患が、フックス角膜内皮ジストロフィである。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
JPWO2017110094JP2018065860EP3395364